Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

162 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-04-15

Study Completion Date

2028-04-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

World Health Organization considers non-adherence has a strong negative impact on the health of patients with chronic diseases. In transplantation, adherence to immunosuppressive drug regimens associates with late rejection and graft loss making it a critical determinant of patient outcome. The prevalence of non-adherence in transplant patients, including liver transplant patients, can be as high as 40%. Among others, life-long intake and complexity of immunosuppressive regimen make patients prone to non-adherence. For instance, non-adherence is more prevalent among patients with higher numbers of immunosuppressive drugs. One of the most commonly cited causes of non-adherence is forgetfulness and disruptions in routine, with the evening dose of twice daily regimens being the most likely to be affected6. Besides non-adherence, the constraints generated in everyday life by immunosuppression (including timely and regular drug intake) and the complexity of the immunosuppressive regimens represent a burden for the patients and are probably associated with a health-related quality of life deterioration. Therefore, long-term adherence and quality of life after liver transplantation might be improved by using a well-tolerated and easy-to-handle immunosuppressive regimen.

The immunosuppressive regimen after liver transplantation is in most cases based on different combinations of tacrolimus, mycophenolate mofetil and corticosteroids. While corticosteroids are administered once daily, tacrolimus can be administered either twice-daily (BID) as an immediate-release, or once-daily (QD) as an extended-release formulation. Among once-daily tacrolimus formulations, LCP-tacrolimus (ENVARSUS XR®) is approved for the prevention of transplant rejection in adult liver allograft recipients. It has demonstrated similar outcomes compared to immediate-release tacrolimus BID, in both kidney and liver transplantation. Mycophenolate has only been approved for BID administration, preventing from taking all immunosuppressive drugs once daily. Yet, single daily dosing would probably contribute to better adherence and quality of life in patients receiving a life-long treatment.

Although the half-life of mycophenolic acid (MPA), the active moiety of mycophenolate mofetil (MMF) is compatible with once-daily administration, no published randomized clinical study has ever evaluated the efficacy and safety of MMF administered QD.

The narrow therapeutic index and wide pharmacokinetic variability of tacrolimus and mycophenolate justify individual dose adjustment by means of therapeutic drug monitoring (TDM), in order to minimize the risk of acute rejection and the occurrence of adverse events. For tacrolimus, TDM is generally based on the trough concentration (C0) and sometimes on the area under the concentration-time curve (AUC), while for mycophenolate it should be based on the AUC of MPA. However, the dose adjustment of MMF in liver transplant patients is most of the time performed a posteriori, based on clinical signs of inefficacy of toxicity.

Limited sampling strategies with maximum a posteriori Bayesian estimation have been developed by our team for both molecules in adult liver transplant patients to estimate their AUC, which is considered the best marker of exposure for both. Therefore, tacrolimus AUC0-24h can be estimated by Bayesian estimation using samples collected before administration (C0), 8 (C8h) and 12 (C12h) hours after the administration of ENVARSUS XR®, or 1 and 3 hours after the administration of PROGRAF® and ADVAGRAF®. For mycophenolate, the MPA AUC can be estimated using samples collected 20 min, 1 and 3 hours after MMF administration, by Bayesian estimation.

Even if limited to 2 or 3 blood samples, tacrolimus TDM for ENVARSUS® requires late sampling (12h post-dose). To overcome the necessity of a longer hospital stay, microsampling devices (MSD) such as the Volumetric absorptive microsampling (VAMS®) device (Mitra®) can be used by the patients to take samples themselves, at home. Moreover, they are less invasive than venipuncture and collect low but accurate volumes of blood for analysis.

In this context, we propose a randomized controlled non-inferiority study to demonstrate that in liver transplant recipients, an immunosuppressive strategy based on single daily doses of LCP-tacrolimus (ENVARSUS XR®) and mycophenolate mofetil (CELLCEPT®) started at M6 post-transplantation is not inferior to XR-tacrolimus (ADVAGRAF®) and MMF administered BID, in terms of incidence of treatment failure (see below) at the end of the first year after transplantation, and to obtain adherence, quality of life and safety data. In order to compare solely MMF QD to MMF BID, patients on ENVARSUS XR® and MMF QD will be compared to a third group of patients receiving ENVARSUS XR® and MMF BID. A direct comparison of efficacy and safety, quality of life, adherence and exposure indices will be performed between ENVARSUS XR® and ADVAGRAF®.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Reduction of Tacrolimus Dose in Association With Mycophenolate Mofetil After Liver Transplantation

NCT00151632

Evidence of Liver Transplantation

TERMINATED PHASE3

Bayesian Dose Adjustment of Immunosuppressants After Lung Transplantation

NCT00975663

Lung and Heart-lung Transplantation

TERMINATED PHASE4

Twice-daily Tacrolimus and Everolimus Convert to Once-daily Tacrolimus and Everolimus in Liver Transplant Recipient

NCT03256864

Liver Transplantation

COMPLETED PHASE4

Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors

NCT00456235

Liver Transplantation

COMPLETED PHASE4

Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients

NCT00105235

Liver Disease Liver Transplantation

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Transplantation Immunosuppression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard of care 1

Group Type ACTIVE_COMPARATOR

XR-tacrolimus QD + MMF BID

Intervention Type DRUG

Patients receive XR-tacrolimus once daily (QD) and MMF twice daily (BID) as per the usual care.

Test 1

Group Type EXPERIMENTAL

XR-tacrolimus QD + MMF BID then MMF QD

Intervention Type DRUG

Patients start on XR-Tacrolimus once daily (QD) and MMF twice daily (BID) as per the usual care. At 6 months post-transplantation (±1 month) MMF administration frequency will be switched from BID to QD, in the morning, at the same daily dose

Test 2

Group Type EXPERIMENTAL

LCP-tacrolimus QD + MMF QD then MMF QD

Intervention Type DRUG

Patients start on LCP-Tacrolimus once daily (QD) and MMF twice daily (BID) as per usual care. At 6 months post-transplantation (±1 month), MMF administration frequency will be switched from BID to QD, in the morning, at the same daily dose

Standard of care 2

Group Type ACTIVE_COMPARATOR

LCP-tacrolimus QD + MMF BID

Intervention Type DRUG

Patients receive LCP-tacrolimus once daily (QD) and MMF twice daily (BID) as per the usual care.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

XR-tacrolimus QD + MMF BID then MMF QD

Patients start on XR-Tacrolimus once daily (QD) and MMF twice daily (BID) as per the usual care. At 6 months post-transplantation (±1 month) MMF administration frequency will be switched from BID to QD, in the morning, at the same daily dose

Intervention Type DRUG

XR-tacrolimus QD + MMF BID

Patients receive XR-tacrolimus once daily (QD) and MMF twice daily (BID) as per the usual care.

Intervention Type DRUG

LCP-tacrolimus QD + MMF QD then MMF QD

Patients start on LCP-Tacrolimus once daily (QD) and MMF twice daily (BID) as per usual care. At 6 months post-transplantation (±1 month), MMF administration frequency will be switched from BID to QD, in the morning, at the same daily dose

Intervention Type DRUG

LCP-tacrolimus QD + MMF BID

Patients receive LCP-tacrolimus once daily (QD) and MMF twice daily (BID) as per the usual care.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Recipients of a first liver allograft from a deceased donor
* Transplanted for less than four weeks at enrolment.
* Without inter-current progressive life-threatening or graft-threatening disease.
* Having signed a written informed consent for their participation in the study.
* Affiliated to, or beneficiary of, a social security regimen

Exclusion Criteria

* Recipients of a split-liver transplantation.
* Recipients of any transplanted organ other than the liver
* Patient who has undergone colon resection
* Patients under legal protection (guardianship, curatorship).
* Patient presenting any contra-indication to tacrolimus or to MMF according to the summary of product characteristics (SmPC) of ENVARSUS®, ADVAGRAF® and CELLCEPT®.
* Patients in whom everolimus-based calcineurin inhibitors (CNI) minimization is anticipated
* Patients treated with HIV or HCV protease inhibitors.
* Pregnant or lactating women.
* Women of childbearing potential without any effective contraceptive method (according to the guidelines of CTFG, Clinical Trial Facilitation Group, related to contraception and pregnancy test in clinical trials) or not practicing sexual abstinence.
* Sexually active men having a female partner, without any effective contraception.
* Patients incapable of understanding the purposes and risks of the study, who cannot give written informed consent, or who are unwilling to comply with the study protocol.
* Patients enrolled in another clinical study evaluating drugs or therapeutic strategies potentially interfering with the objectives of the EASY study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No